GeoVax Labs Advances Vaccine Development with Promising Financial and Clinical Updates

GeoVax Labs, Inc. has recently shared its second quarter 2025 financial results, alongside a business update that highlights notable progress in its vaccine and immunotherapy pipeline. The company received favorable regulatory guidance from the European Medicines Agency for GEO-MVA, its vaccine aimed at preventing Mpox and smallpox, which could significantly expedite its development process. This development is particularly timely, given the World Health Organization's classification of Mpox as a public health emergency of international concern. GeoVax plans to commence a Phase 3 trial for GEO-MVA in the latter half of 2026, targeting a market with potential exceeding $10 billion.

In addition to GEO-MVA, GeoVax's next-generation COVID-19 vaccine, GEO-CM04S1, has demonstrated encouraging results in immunocompromised patients, including those with Chronic Lymphocytic Leukemia (CLL). The vaccine elicited robust SARS-CoV-2 Nucleocapsid-specific IgG and T cell responses, findings that were presented at the American Association of Immunology 2025 Annual Meeting. These results underscore the vaccine's potential to offer dual protection against COVID-19 and Mpox, marking a significant advancement in the fight against these viruses.

On the oncology front, Gedeptin®, GeoVax's gene-directed prodrug therapy for solid tumors, has shown strong safety and efficacy profiles in heavily pretreated patients. Data presented at the American Association for Cancer Research Annual Meeting revealed a median progression-free survival and overall survival of 7.0 months, addressing a critical gap in oncology treatment options. Furthermore, GeoVax has expanded its intellectual property portfolio with new patents covering a malaria vaccine construct and the combination of Gedeptin therapy with radiation for solid tumors.

The company's financial results for the second quarter of 2025 reflect its commitment to advancing its research and development efforts. With a net loss of $5,369,783, or $0.35 per share, and government contract revenues of $852,282, GeoVax continues to invest in the development of innovative vaccines and therapies. These advancements not only highlight the company's progress in addressing unmet medical needs but also its potential to make a significant impact on public health globally.